Quentin M Anstee is Professor of Experimental Hepatology at Newcastle University. A practising clinician, he is also an Honorary Consultant Hepatologist in the Liver Unit with the Newcastle upon Tyne Hospitals NHS Foundation Trust, where he leads one of the largest NAFLD clinical services in the UK.

His translational research has extended from the bench to the bedside with particular focus on the pathogenesis, diagnosis and treatment of Non-Alcoholic Fatty Liver Disease & Steatohepatitis (NAFLD/NASH), including the identification of genetic and epigenetic modifiers of disease progression and Hepatocellular Carcinoma (HCC) risk.

Prof Anstee oversaw the EU FP7 funded ‘FLIP’ Fatty Liver: Inhibition of Progression consortium genetics work-package. He now leads two major EU funded international research consortia that are studying NAFLD pathogenesis and developing/validating biomarkers to assist the diagnosis, risk-stratification and monitoring of patients with NAFLD: ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (EU IMI2 funded €34 million, 2017-2022) and ‘EPoS’ Elucidating Pathways of Steatohepatitis (EU H2020 funded €6 million, 2015-2019). He is also Chief Investigator of the European NAFLD Registry and several ongoing Phase 2/3 clinical trials examining new medical therapies for NAFLD.